Abstracts tagged "Myopathies"

Abstract Number: 0176 • ACR Convergence 2022
Diagnostic Accuracy and Clinical Relevance of Muscle Biopsy in Patients with Suspected Myositis
Kastriot Kastrati¹, Nasim NAKHOST LOTFI², Marwa Tawfik³, Ellen Gelpi², Romana Hoeftberger², Hans-Peter Kiener², Daniel Aletaha⁴, Michael Bonelli⁵ and Helga Radner⁵, ¹Division of Rheumatology, Vienna, Austria, ²Medical University Vienna, Vienna, Austria, ³Suez Canal University, Ismailia, Egypt, ⁴Medical University Vienna, Wien, Austria, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Diagnosis of idiopathic inflammatory myopathies (IIM) represents a clinical challenge and muscle biopsy is regarded as a fundamental procedure for confirming diagnosis. However, the…
Abstract Number: 0177 • ACR Convergence 2022
COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey
Mrinalini Dey¹, Naveen R², Elena Nikiphorou³, Parikshit Sen⁴, James B. Lilleker⁵, Vishwesh Agarwal⁶, Sinan Kardes⁷, Jessica Day⁸, Marcin Milchert⁹, Mrudula Joshi¹⁰, Tamer A Gheita¹¹, Babur Salim¹², Tsvetelina Velikova¹³, Abraham Edgar Gracia-Ramos¹⁴, Ioannis Parodis¹⁵, Albert Selva O’Callaghan¹⁶, Minchul Kim¹⁷, Tulika Chatterjee¹⁷, Ai Lyn Tan¹⁸, Ashima Makol¹⁹, Arvind Nune²⁰, Lorenzo Cavagna²¹, Miguel Angel Saavedra Salinas²², Samuel Shinjo²³, Nelly Ziade²⁴, Johannes Knitza²⁵, Masataka Kuwana²⁶, Oliver Distler²⁷, Hector Chinoy²⁸, John Pauling²⁹, Chris Wincup³⁰, Vikas Agarwal², Rohit Aggarwal³¹ and Latika Gupta³², ¹Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Leiden University Medical Center & King's College London, London, United Kingdom, ⁴Maulana Azad Medical College, New Delhi, India, ⁵The University of Manchester, Manchester, United Kingdom, ⁶Mahatma Gandhi Missions Medical College, Lucknow, India, ⁷Istanbul University, Istanbul, Turkey, ⁸Walter and Eliza Hall Institute, Melbourne, Australia, ⁹Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁰Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹²Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, ¹³Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁴Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, ¹⁵Karolinska Institutet, Stockholm, Sweden, ¹⁶Hospital Universitari Vall d'Hebron, Barcelona, Spain, ¹⁷University of Illinois College of Medicine Peoria, Peoria, IL, ¹⁸University of Leeds, Leeds, United Kingdom, ¹⁹Mayo Clinic, Rochester, MN, Rochester, MN, ²⁰Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, ²¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, ²²IMSS, Ciudad de México, Mexico, ²³Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ²⁴Saint-Joseph University, Beirut, Lebanon, ²⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²⁶Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²⁸The University of Manchester, Sale, United Kingdom, ²⁹North Bristol NHS Trust, Bristol, United Kingdom, ³⁰Rayne Institute, University College London, London, United Kingdom, ³¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³²Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom
Background/Purpose: COVID-19 vaccines are safe and effective, though patients with rare rheumatic diseases like idiopathic inflammatory myositis (IIMs), and those with multiple comorbidities continue to…
Abstract Number: 0940 • ACR Convergence 2022
Effect of an 8-week Tailored Physical Therapy Program on Sexual Function in Women with Systemic Sclerosis and Idiopathic Inflammatory Myopathies: A Pilot Controlled Study
Barbora Hermankova¹, Maja Spiritovic¹, Sabina Oreska², Hana Storkanova², Karel Pavelka³, Ladislav Šenolt⁴, Jiří Vencovský⁴, Radim Becvar² and Michal Tomcik², ¹Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic rheumatic diseases like systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM) may affect all aspects of life, including sexual health. However, no non-pharmacological…
Abstract Number: 1233 • ACR Convergence 2022
Ultrasound Is Reliable in the Assessment of Muscle Echogenicity in Patients with Rheumatic Diseases: Results of a Multicenter International Web-based Study
Andrea Di Matteo¹, Erica Moscioni², Maria Giovanna Lommano¹, Edoardo Cipolletta¹, Gianluca Smerilli¹, Sonia Farah¹, Carla Airoldi³, Sibel Aydin⁴, Becciolini Andrea⁵, Karina Bonfiglioli⁶, Marina Carotti⁷, Greta Carrara⁸, Tomas Cazenave⁹, Davide Corradini¹⁰, Micaela Ana Cosatti¹¹, Juan Josè de Agustin¹², Giulia Maria Destro Castaniti¹³, Marco Di Carlo¹, Eleonora Di Donato⁵, Luca Di geso¹⁴, Ashley Elliott¹⁵, Daniela Fodor¹⁶, Francesca Francioso¹, Alessandra Gabba¹⁷, Cristina Hernández-Díaz¹⁸, Rudolf Horvath¹⁹, Jana Hurnakova¹⁹, Diogo Jesus²⁰, Josefina Marin²¹, Maria Victoria Martire²², Riccardo Mashadi-Mirza²³, Marco Massarotti²⁴, Alice Andreea Musca²⁵, Jagdish Nair²⁶, Tadashi Okano²⁷, Ioannis Papalopoulos²⁸, Javier Eduardo Rosa²¹, Marcos Rosemffet²⁹, João Rovisco³⁰, Davide Rozza⁸, Fausto Salaffi¹, Crescenzio Scioscia³¹, Carlo Alberto Scirè⁸, Maria-Magdalena Tamas³², Shun Tanimura³³, Lucio Ventura-Rios¹⁸, Catalina Villota-Eraso³⁴, Orlando Villota³⁵, Paraksevi V Voulgari³⁶, Florentin Ananu Vreju³⁷, Gentiana Vukatana³⁷, Johana Zacariaz Hereter²¹, Anna Zanetti⁸, Walter Grassi¹ and Emilio Filippucci¹, ¹Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi, Italy, ²Polytechnic University of Marche, Jesi, Italy, ³Hospital Provincial, Rosario, Argentina, ⁴University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada, ⁵Department of Medicine, Internal Medicine and Rheumatology Unit, Azienda Ospedaliero Universitaria di Parma, Parma, Italy, ⁶Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Department of Radiology, Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy, ⁸Epidemiology Unit, Italian Society of Rheumatology, Milano, Italy, ⁹Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ¹⁰Rheumatology Unit, University Clinic AOU Cagliari, Cagliari, Italy, ¹¹CEMIC, Centro de educación médica e investigaciones médicas "Norberto Quirno", Buenos Aires, Argentina, ¹²Vall D'hebron University Hospital, Barcelona, Spain, ¹³Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology section, University of Palermo, Palermo, Italy, ¹⁴Ospedale Madonna del Soccorso, Department of Internal Medicine, San Benedetto del Tronto, Italy, ¹⁵Centre for Experimental Medicine, Queen's University, Belfast, Northern Ireland, United Kingdom, ¹⁶2nd Internal Medicine Department, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania, ¹⁷Local Health Unit (ASL), Oristano, Italy, ¹⁸Division de Reumatologia. Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ¹⁹Department of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czech Republic, ²⁰Rheumatology Department, Centro Hospitalar de Leiria, Leira, Portugal, ²¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²²San Roque Hospital, La Plata, Buenos Aires, Argentina, ²³Radiology Department, A.O. Ospedali Riuniti Marche Nord, Pesaro, Italy, ²⁴Department of Rheumatology, University Hospitals Dorset NHS Foundation Trust, Christchurch Hospital, Christchurch, United Kingdom, ²⁵Department of Rheumatology - Colentina Clinical Hospital, Bucharest, Romania, ²⁶Rheumatology, Liverpool University Hospitals Foundation Trust, Liverpool, United Kingdom, ²⁷Department of Orthopedic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ²⁸Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, ²⁹Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ³⁰Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³¹Department of Emergency and Organ Transplantations-Rheumatology Unit, University of Bari "Aldo Moro", Bari, Italy, ³²Department of Rheumatology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania, ³³Rheumatology Department, Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan, ³⁴IPS Servicio integral de reumatología e inmunología Dr Orlando Villota, Pasto, Colombia, ³⁵Division of Rheumatology, Fundación Hospital San Pedro, Pasto, Colombia, ³⁶Department of Rheumatology, School of Health Science, Faculty of Medicine, University of Ioannina, Ioannina, Greece, ³⁷Rheumatology Department, University of Medicine and Pharmacy of Craiova, Craiova, Romania, ³⁷Rheumatology Unit; IRCCS Policlinico S. Orsola Malpighi, Bologna, Italy
Background/Purpose: Studies have showed that an increased ultrasound (US) muscle echogenicity indicating fatty replacement/fibrosis of muscle tissue may represent an early indicator of muscle involvement associated…
Abstract Number: 1283 • ACR Convergence 2022
Frequency of Checking Creatine Kinase in Patients on Statins with Elevated Transaminase for Early Detection of Statin Induced Myopathy
ANJALI NIDHAAN, Andrei Hastings, david gonzalez, rajshri joshi, nathan gilbert and carolyn o'connor, Cleveland Clinic Akron General, Akron, OH
Background/Purpose: Some of the most commonly reported side effects of statins (widely used lipid lowering agents) are muscle injury (incidence ranging from 0.1-20% based on…
Abstract Number: 0701 • ACR Convergence 2021
Use and Yield of Computed Tomography as a Cancer Surveillance Method in Idiopathic Inflammatory Myositis
Christopher Mecoli¹, Brant Chee², XingYao Wang³, Mengkun Chen⁴, William Kelly³, Elizabeth Platz⁴, Livia Casciola-Rosen⁵, Lisa Christopher-Stine³ and Ami Shah⁶, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Applied Physics Laboratory, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Public Health, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: To inform guidance for cancer surveillance in patients with idiopathic inflammatory myositis (IIM), we conducted a retrospective cohort study in a single tertiary referral…
Abstract Number: 0704 • ACR Convergence 2021
Anti-SSa/SSb and Ro52 and Interstitial Lung Disease in Idiopathic Inflammatory Myopathies
Sonali Narain¹, Ana Valle², Maria-Louise Barilla-Labarca¹ and Galina Marder³, ¹Northwell Health, Great Neck, NY, ²Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, ³Division of Rheumatology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: In idiopathic inflammatory myopathies (IIM), SSa/SSb and Ro52 antibodies are frequently reported, especially in association with interstitial lung disease (ILD). However, limited literature exists…
Abstract Number: 0706 • ACR Convergence 2021
Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis
Madison Grinnell¹, Emily Keyes², DeAnna Diaz², Thomas Vazquez³, Rui Feng⁴ and Victoria Werth², ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ³FIU Wertheim College of Medicine, Virginia Beach, VA, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Treatment of dermatomyositis (DM) typically follows a stepwise sequence starting with either methotrexate (MTX) or mycophenolate mofetil (MMF) after an inadequate response to antimalarial…
Abstract Number: 0707 • ACR Convergence 2021
Association of Pneumomediastinum with Poor Prognosis in Patients with Myositis-Associated Interstitial Lung Disease
Kazuki Hirano¹, Azusa Kojima¹, Akira Ishii¹, Mai Sugiyama¹, Yuto Izumi¹, Noriko Sasaki², Yuji Hosono¹, Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Pneumomediastinum is an important complication in patients with myositis-associated interstitial lung disease (ILD). Patients with myositis and ILD who had pneumomediastinum during the disease…
Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Hortense Chassepot¹, Lotta Plomp², Dimitri Psimaras³, Thierry Maisonobe³, Sarah Leonard Louis⁴, Isabelle Plu⁴, Mehdi Touat³, Celine Anquetil⁵, Nadege Wesner⁵, Nicolas Champtiaux⁵, Aude Rigolet⁵, Sophie Demeret³, Nicolas Weiss³, Baptiste Abbar⁶, Marie-Claire Bretagne⁷, Bruno Pinna⁷, Capucine Morelot⁸, Martin Dres⁸, Thomas Similowski⁸, Stephane Ederhy⁹, Joe-Elie Salem⁷, Olivier Benveniste⁵ and Yves Allenbach⁵, ¹Universite de Picardie Jules Verne UPJV - Amiens Picardie Hospital, Department of Clinical Immunology and Internal Medicine, Fourqueux, France, ²Amsterdam University Medical Center (AUMC), Amsterdam, Netherlands, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ⁵Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁶Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, Paris, France, ⁷Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France, ⁸Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology - R3S, Paris, France, ⁹Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Cardiology, Paris, France
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…
Abstract Number: 0718 • ACR Convergence 2021
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
Harmony Tsui¹, Mianbo Wang², Mathieu Piché³, Alexandra Ladouceur⁴, Evelyne Vinet⁵, Alexandra Albert⁶, Maggie Larche⁷, Annaliese Tisseverasinghe⁸, Marie Hudson¹ and Valerie Leclair⁹, ¹McGill University, Montréal, QC, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada, ⁴McGill University Health Center, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada, ⁶CHU de Quebec, Québec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹McGill University, Karolinska Insitutet, Montréal, QC, Canada
Background/Purpose: Although pain is one of the most common and highest priority symptoms reported by people with autoimmune inflammatory myopathies (AIM), large descriptive studies on…
Abstract Number: 0441 • ACR Convergence 2021
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Pedro Machado¹, Richard Barohn², Michael McDermott³, Thomas Blaetter⁴, Tom Lloyd⁵, Aziz Shaibani⁶, Miriam Freimer⁷, Anthony Amato⁸, Emma Ciafaloni³, Sarah Jones⁹, Tahseen Mozaffar¹⁰, Summer Gibson¹¹, Matthew Wicklund¹², Todd Levine¹³, Claus Sundgreen⁴, Tim Carstensen⁴, Karen Bonefeld⁴, Anders Jørgensen⁴, Karina Phonekeo⁴, Andrew Heim¹⁴, Laura Herbelin¹⁴, Michael Hanna¹⁵ and Mazen Dimachkie¹⁴, ¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²University of Missouri - Columbia, Columbia, MO, ³University of Rochester, Rochester, NY, ⁴Orphazyme A/S, Copenhagen, Denmark, ⁵Johns Hopkins University, Baltimore, MD, ⁶Nerve and Musle Center, Houston, TX, ⁷Ohio State University, Columbus, OH, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Virginia, Charlottesville, VA, ¹⁰University of California Irvine, Irvine, CA, ¹¹University of Utah, Salt Lake City, UT, ¹²University of Colorado, Denver, CO, ¹³Phoenix Neurological Associates, Phoenix, AZ, ¹⁴University of Kansas Medical Center, Kansas City, KS, ¹⁵University College London, London, United Kingdom
Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
Abstract Number: 0443 • ACR Convergence 2021
Safety and Efficacy of Belimumab in the Treatment of Adult Idiopathic Inflammatory Myositis (Polymyositis and Dermatomyositis)
Priyal Chadha¹, Sonali Narain², Preeya Nandkumar³, Cristine Sison⁴, Elena Schiopu⁵, Todd Levine⁶, James Tsang⁷ and Galina Marder⁸, ¹SUNY Upstate Medical University, Syracuse, NY, ²Northwell Health, Great Neck, NY, ³Division of Rheumatology, Department of Medicine, Northwell, Great Neck, NY, ⁴Biostatistics Unit , Department of Molecular Medicine, Feinstein Institutes for Medical Research at Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵University of Michigan, Ann Arbor, MI, ⁶Phoenix Neurological Associates, Phoenix, AZ, ⁷Center for Research Informatics & Innovation (CRII), Feinstein Institute for Medical Research at Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁸Division of Rheumatology, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Treatment of Idiopathic Inflammatory Myositis (IIM) includes steroids and immunosuppressive agents. Targeting IL6, IL1, TNF for treatment of IIM has not been successful, and…
Abstract Number: 0697 • ACR Convergence 2021
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Angeles Shunashy Galindo-Feria¹, Begum Horuluoglu¹, Jessica Day², Catia Cerqueira³, Edvard Wigren⁴, Susanne Gräslund⁴, Susanna Proudman⁵, Ingrid E Lundberg⁴ and Vidya Limaye⁶, ¹Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³4Dcell, Montreuil, France, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵University of Adelaide, Medindie, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…
Abstract Number: 1062 • ACR Convergence 2020
Dermatomyositis: A Dermatology-Rheumatology Clinic Retrospective Analysis
Burak Elkiran¹, Mahroo Tajalli², Terrence M. Vance³, Abrar A. Qureshi⁴ and Anthony M. Reginato⁵, ¹Department of Medicine, Division of Rheumatology; Warren Alpert Medical School of Brown University, BOSTON, ²Department of Dermatology, Warren Alpert Medical School of Brown University, PROVIDENCE, ³Department of Epidemiology, Warren Alpert Medical School of Brown University, PROVIDENCE, ⁴Department of Dermatology, Warren Alpert Medical School of Brown University, BOSTON, ⁵Department of Medicine, Division of Rheumatology, Warren Alpert Medical School of Brown University, Boston, MA
Background/Purpose: Dermatomyositis (DM) can be categorized into two major subtypes: clinically amyopathic dermatomyositis (CADM) and classic dermatomyositis (CDM). In this study, we aimed to identify characteristics…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].